| Literature DB >> 28928355 |
Juan Ignacio Tellechea1, Jean-Michel Gonzalez1, Pablo Miranda-García1, Adrian Culetto1, Xavier Benoit D'Journo2, Pascal Alexandre Thomas2, Marc Barthet1.
Abstract
Boerhaave syndrome (BS) is a spontaneous esophageal perforation which carries high mortality. Surgical treatment is well established, but the development of interventional endoscopy has proposed new therapies. We expose our experience in a Gastrointestinal and Endoscopy Unit. With a retrospective, observational, open-label, single center, consecutive case series. All patients diagnosed with BS who were managed in our center were included. Treated conservatively, endoscopically or surgically, according to their clinical condition and lesion presentation. Fourteen patients were included. Ten were treated with primary surgery. One conservatively. In total, 7/14 patients required an endoscopic treatment. All required metallic stents deployment, 3 cases over-the-scope-clips concomitantly and one case a novel technique an internal drain. 6/7 cases endoscopically treated achieved complete esophageal healing. In conclusion, endoscopy is an useful tool at all stages BS management: difficult diagnosis, primary treatment in selected patients and as salvage when surgery fails. With mortality rates and outcomes comparables to surgery.Entities:
Keywords: Endoscopy; Esophageal perforation; Minimally invasive surgical procedures; Stents; Surgical instruments
Year: 2017 PMID: 28928355 PMCID: PMC5903076 DOI: 10.5946/ce.2017.043
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Step-by-Step Details of the Surgical and Endoscopic Procedures including Technical Characteristics and Complications
| Case No. | Year | Conduct | Complication |
|---|---|---|---|
| 1 | 2004 | Drain[ | Suture dehiscence |
| AR-FCMS[ | Stent migration | ||
| AR-FCMS[ | |||
| AR-FCMS[ | |||
| Treatment success, discharge | Post-stent stenosis | ||
| 2 | 2008 | Diagnostic | |
| Drains[ | |||
| Treatment success, discharge | |||
| 3 | 2010 | Diagnostic | |
| Conservative treatment | |||
| Treatment success, discharge | |||
| 4 | 2010 | Drains[ | |
| Diagnostic | |||
| ES | |||
| Treatment success, discharge | |||
| 5 | 2011 | Drain[ | |
| CMS[ | Stent migration | ||
| FCMS[ | Stent migration | ||
| FCMS[ | |||
| Treatment success, discharge | |||
| 6 | 2011 | Diagnostic | |
| Drain[ | |||
| Treatment success, discharge | |||
| 7 | 2011 | Diagnostic | |
| Drain[ | |||
| Treatment success, discharge | |||
| 8 | 2012 | Diagnostic | Died first 24 hr post treatment |
| Drain[ | |||
| 9 | 2013 | Drain[ | |
| Diagnostic | |||
| Drain[ | |||
| Treatment success, discharge | Pneumonia, eventration | ||
| 10 | 2013 | Drain[ | Died first 24 hr post treatment |
| 11 | 2014 | Drain[ | Suture leakage |
| ES + Fundoplication reinforcement | |||
| FCMS[ | |||
| Treatment success, discharge | |||
| 12 | 2014 | Drain[ | Stent migration |
| FCMS re-fixed w/3 clips[ | |||
| Treatment success, discharge | Post-stent stenosis | ||
| 13 | 2015 | LP + local ATB + OTSC[ | Suture dehiscense |
| LP + local ATB + FCMS[ | |||
| LP + naso-cystic internal drain | |||
| LP + local ATB + FCMS[ | |||
| LP + naso-cystic internal drain | |||
| Drain in place + double pig tail plastic stent[ | Cysto-bronchial fistula | ||
| Drain in place + FCMS[ | |||
| Metallic stent removal + naso-cystic drain in place + oral refeeding, discharge | |||
| 14 | 2015 | Drain[ | |
| ES | Suture leakage | ||
| Drain[ | Insufficient closure | ||
| LP + FCMS[ | |||
| Discharge | |||
| Endoscopic control: in place and permeable stent | |||
| Metallic stent removal + control: fistula closure |
Nasogastric tube for esophageal aspiration.
ES, oversewing/primary suture; AR-FCMS, anti-reflux fully covered metallic stent; CMS, covered metallic stent; endoscopic mediastinal cavity lavage; LP, endoscopic pleural cavity lavage; OTSC, over-the-scope-clips; ATB, amikacin (local), augmentin (amoxicillin+clavulanic acid, IV).
Previous surgical external drain.
Hanarostent; Life Partners Europe, Bagnolet, France.
Ultraflex NG covered; Boston Scientific, Marlborough, MA, USA.
Niti S enteral colonic; TaeWoong Medical, Seoul, Korea.
Niti S double; TaeWoong Medical, Seoul, Korea.
Ovesco Endoscopy AG, Tübingen, Germany.
Niti S; TaeWoong Medical, Seoul, Korea.
Cook, Bloomington, IN, USA.
Previous computed tomography-guided percutaneous drain.
Population, Clinical Onset, Diagnosis, and Endoscopic Findings
| Gender | 4 F/ 10 M |
| Mean age | 65, 21 yr (range, 41–82 yr) |
| Procedence | 57.14% transferred from another hospital |
| Admission | 92.85% at the urgency unit |
| Primary symptom | 9/14 vomiting and chest or abdominal pain |
| Diagnosis method | 11/14 patients (78%) was achieved with CT scan |
| Debut symptoms to | 7/14 (50%) <24 hr |
| Endoscopy | 3/14 between 24 hr, 4 days |
| 4/14 longer time to endoscopy: 6, 16, 40, 60 days (due to prior surgery or a delayed derivation) | |
| Endoscopic findings | 11/14 lower esophagus |
| 3/14 esophago-gastric junction | |
| Lesion localisation | Lower esophagus: 6/11 left side, 4/11 anterior, 1/11 posterior |
| 33% localized at erythematous or ulcerated mucosa | |
| Median lesion size | 3 cm (range, 0.3–5 cm) |
| CO2 Insuflator | From 2013 all procedures were made with this device |
CT, computed tomography; CO2, carbon dioxide.
Fig. 1.Global management strategies, progression, and outcomes. CT, computed tomography; ES, oversewing/primary suture.
Treatment Outcomes: Clinical Success Rates, Treatment Time, Number Procedures, Follow up, Number of Complications
| Surgical therapy | Endoscopic therapy | |
|---|---|---|
| Clinical success (%) | 50 | 85 |
| Median time of treatment: mo (range) | 1 (1–2) | 3 (1–8) |
| Median number of procedures to achieve success | 1, 4 (1–2) | 3 (1–8) |
| Median time of follow up: mo (range) | 6 (2–12) | 6 (2–12) |
| Number of deaths | 1 | 1 |
| Complications (numbers) | 1 | 3 |